Biohaven officer reports initial share holdings
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Biohaven Ltd. officer Warren Karl Volles filed an initial statement of beneficial ownership. As of July 9, 2026, he directly owned 248,212 Common Shares, including shares acquired through the Biohaven Employee Share Purchase Plan. He also held 14,000 restricted share units and stock options over Common Shares, including options on 300,000 shares at $7.00 expiring in 2032 and on 95,250 shares at $41.93 expiring in 2034, with additional option tranches vesting through 2029.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Volles Warren Karl
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Options (Right to buy) F2 | -- | -- | -- |
| Holding | Stock Options (Right to buy) F3 | -- | -- | -- |
| Holding | Stock Options (Right to buy) F4 | -- | -- | -- |
| Holding | Stock Options (Right to buy) F5 | -- | -- | -- |
| Holding | Stock Options (Right to buy) F6 | -- | -- | -- |
| Holding | Restricted Share Unit Award F9, F7, F8 | -- | -- | -- |
| Holding | Common Shares F1 | -- | -- | -- |
Holdings:
Stock Options (Right to buy) — 732,000 options (Direct);
Restricted Share Unit Award — 14,000 units (Direct);
Common Shares — 248,212 shares (Direct)
Footnotes (9)
- F1. This balance includes 742 shares, 1,086 shares, 2 shares, and 2,500 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2024, May 31, 2025, November 30, 2025, and May 31, 2026, respectively.
- F2. The shares underlying this option became exercisable on and prior to October 3, 2025.
- F3. The shares underlying this option became exercisable as to 59,063 of these shares on and prior to November 2, 2025, with the remainder vesting on November 2, 2026, subject to the Reporting Person's continued service with the Issuer at the vesting date.
- F4. The shares underlying this option became exercisable as to 72,188 of these shares on and prior to January 2, 2026, with the remainder vesting on January 2, 2027, subject to the Reporting Person's continued service with the Issuer at the vesting date.
- F5. The shares underlying this option became exercisable as to 41,500 of these shares on and prior to January 5, 2026, with the remainder vesting in two equal installments on January 5, 2027, and 2028, subject to the Reporting Person's continued service with the Issuer at each vesting date.
- F6. The shares underlying this option became exercisable as to 43,750 of these shares on February 27, 2026, with the remainder vesting in three equal installments on February 27, 2027, 2028, and 2029, subject to the Reporting Person's continued service with the Issuer at each vesting date.
- F7. The reporting person was granted 14,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027, and 2028, subject to the Reporting Person's continued service with the Issuer at each vesting date.
- F8. Not applicable.
- F9. Each restricted share unit represents the contingent right to receive one common share of the Issuer.
Key Figures
Direct Common Shares Owned: 248,212 Common Shares
Restricted Share Units: 14,000 underlying Common Shares
Stock Options at $7.00: 300,000 underlying Common Shares at $7.00
+4 more
7 metrics
Direct Common Shares Owned
248,212 Common Shares
Direct ownership as of July 9, 2026
Restricted Share Units
14,000 underlying Common Shares
Restricted share unit award granted January 5, 2025
Stock Options at $7.00
300,000 underlying Common Shares at $7.00
Stock options expiring October 3, 2032
Stock Options at $29.49
78,750 underlying Common Shares at $29.49
Stock options expiring November 2, 2033
Stock Options at $41.93
95,250 underlying Common Shares at $41.93
Stock options expiring January 2, 2034
Stock Options at $38.64
83,000 underlying Common Shares at $38.64
Stock options expiring January 5, 2035
Stock Options at $11.52
175,000 underlying Common Shares at $11.52
Stock options expiring February 27, 2036
Key Terms
Biohaven Employee Share Purchase Plan, restricted share units, Stock Options (Right to buy), contingent right
4 terms
Stock Options (Right to buy) financial
"security_title": "Stock Options (Right to buy)""
contingent right financial
"Each restricted share unit represents the contingent right to receive one common share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What derivative awards does Warren Karl Volles hold in Biohaven Ltd. (BHVN)?
He holds 14,000 restricted share units, each representing one common share, and multiple stock option awards over common shares. These options cover blocks of 300,000, 78,750, 95,250, 83,000 and 175,000 underlying shares at various exercise prices.
When do Warren Karl Volles' major Biohaven (BHVN) stock options expire?
Reported stock options over Biohaven common shares have expiration dates of October 3, 2032, November 2, 2033, January 2, 2034, January 5, 2035 and February 27, 2036. Portions of these grants are already exercisable, with remaining tranches vesting through 2029.
What is Warren Karl Volles' role at Biohaven Ltd. (BHVN)?
Warren Karl Volles is reported as an officer of Biohaven Ltd., serving as Chief Legal Officer. His initial ownership statement covers his direct holdings of common shares, restricted share units and stock options associated with that executive role.
AI-generated analysis. How Rhea-AI works. Not financial advice.
